(Q53675901)

English

Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.

scientific article published in July 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. (English)

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

immunohistochemistry

1 reference

based on heuristic

inferred from title

papillary carcinoma

1 reference

based on heuristic

inferred from title

author name string

Alessandro D Santin

1

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Stefania Bellone

2

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Sue Van Stedum

3

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Wendy Bushen

4

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Luis E De Las Casas

5

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Soheila Korourian

6

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Erming Tian

7

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Juan J Roman

8

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Alexander Burnett

9

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Sergio Pecorelli

10

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

language of work or name

0 references

publication date

1 July 2005

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Gynecologic Oncology

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

98

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

24-30

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

1

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Endometrial papillary serous carcinoma: patterns of spread and treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Uterine papillary serous carcinoma: patterns of metastatic spread

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Role of HER receptors family in development and differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

HER-2/neu expression: a major prognostic factor in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

HER-2/neu amplification and overexpression in endometrial carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Her-2/neu overexpression and amplification in uterine papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Racial differences in survival of women with endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Theories of endometrial carcinogenesis: a multidisciplinary approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

HER-2 gene amplification can be acquired as breast cancer progresses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Identifiers

10.1016/J.YGYNO.2005.03.041

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53675901&oldid=1524503006"